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eTable. Current Cervical Cancer Screening Guidelines for Women Aged 21 to 65 Years: US Preventive Services Task Force 
(USPSTF, 2018)1, American College of Obstetricians and Gynecologists (ACOG, 2016)2, American Cancer Society/American Society 
for Colposcopy and Cervical Pathology/American Society for Clinical Pathologists (2012)3 
Population Age to begin 
screening 
Screening method and intervals, by age Age to end screening Screening after 
hysterectomy with 
removal of the cervix 
Average-riska women 21 Ages 21-65: cytology every 3y 
or 
Ages 21-29: cytology every 3y 
Ages 30-65: cytology plus hrHPV testing 
every 5y 
or 
Ages 21-29: cytology every 3y 
Ages 30-65: hrHPV testing every 5yb 
65, if 3 consecutive 
negative cytology results 
or 2 consecutive negative 
cytology plus hrHPV 
tests within 10 years with 
the most recent test 
performed within 5 years 
Not recommended 
Women immunocompromised by 
HIV infectionc 
Within 1 year of 
onset of sexual 
activity or, if already 
sexually active, 
within the first year 
after HIV diagnosis 
but no later than 21 
Ages 21-65: cytology every year; after 3 
consecutive annual normal cytology test 
results, screening can be every 3y 
or 
Ages 21-29: cytology as above 
Ages 30-65: cytology plus hrHPV testing 
every 3y 
None; lifelong screening 
recommended 
Not specified 
Women with a diagnosis of 
CIN2+ within the prior 20 yearsd 
Not applicable Routine age-based screening after initial 
post-treatment surveillance period, even if 
it extends past age 65 
May end at age 65 if 
CIN2+ diagnosis ≥20 
years ago and criteria for 
ending screening met 
(above) 
Cytology alone for at 
least 20 years after 
initial post-treatment 
surveillance period 
Women with in utero exposure to 
diethylstilbestrold 
Not specified Annual cytology screening Not specified Not specified 
Abbreviations: hrHPV, high-risk human papillomavirus; HIV, human immunodeficiency virus; CIN2+, cervical intraepithelial neoplasia grade 2, grade 3, 
adenocarcinoma in situ or cervical cancer 
a Women with no prior diagnosis of CIN2+, women who are not immunocompromised and women with no in utero exposure to diethylstilbestrol 
b Per USPSTF; considered an alternative strategy for women aged 25 and older by ACOG 
c Per ACOG, based on recommendations by the Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents4; ACOG guidelines state that it is 
reasonable to extrapolate the recommendations for women with HIV infection to those who are immunocompromised due to non-HIV causes such as solid organ 
transplantation.  
d Per ACOG 
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